Carregant...

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092

As a critical component in the PI3K/AKT/mTOR pathway, AKT has become an attractive target for therapeutic intervention. ARQ 092 and a next generation AKT inhibitor, ARQ 751 are selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors that potently inhibit phosphorylation of AKT. Biochemical an...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS One
Autors principals: Yu, Yi, Savage, Ronald E., Eathiraj, Sudharshan, Meade, Justin, Wick, Michael J., Hall, Terence, Abbadessa, Giovanni, Schwartz, Brian
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2015
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4607407/
https://ncbi.nlm.nih.gov/pubmed/26469692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0140479
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!